血管紧张素Ⅰ转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂对延缓房颤从初发到持续的治疗价值

Prospective Study of Delaying Atrial Fibrillation from Initiation to Persistence with Angiotensin-converting Enzyme Inhibitor or Angiotensin Ⅱ Receptor Antagonist

目的探讨血管紧张素I转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂对房颤从初发到持续的延缓作用。方法对9 l例初发房颤患者依血管紧张素Ⅰ转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂的使用情况,分为治疗组和对照组。随访观察第6、12、18、24个月的维持窦性心律情况。结果治疗组在服用ACEI或ARB后第18、24个月的维持窦性心律情况优于对照组(P<0.05)。结论初发房颤后可使用ACE I或ARB来维持窦性心律,延缓初发到持续的过程,改善预后。

Objective To study the delaying effect of angiotensin - converting enzyme inhibitor （ACEI） or angiotensin Ⅱ receptor antagonist （ARA） on atrial fibrillation from initiation to persistence. Methods A total of 91 patients with atrial fibrillation were divided into trial group and control group according to the usage of ACEI and ARA. The patients of the trial group kept on using ACEI or ARB and all the patients were followed up for 24 months. Results The rate of sinus rhythm in the trial group was significantly higher than that in the control group after 18 and 24 months, respectively （96% VS 82% , P 〈0.05 ; 89% VS 70% , P 〈005）. Conclusion ACEI or ARA can delay the proceeding of atrial fibrillation from initiation to persistence.